AOP-Wiki

API

All KERs

Showing 2951 to 2975 of 3158 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

1908	1493: Increased pro-inflammatory mediators	1182: Increase, Cell Proliferation (Epithelial Cells)	May 10, 2019	May 10, 2019	2 AOPs 294: Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer 293: Increased DNA damage leading to increased risk of breast cancer
1830	55: Cell injury/death	1548: Necrotic Tissue	Jan 7, 2019	Mar 7, 2019	2 AOPs 278: IKK complex inhibition leading to liver injury 273: Mitochondrial complex inhibition leading to liver injury
1835	1582: Impaired axonial transport	1583: Sensory axonal peripheral neuropathy	Jan 29, 2019	Jan 29, 2019	2 AOPs 279: Microtubule interacting drugs lead to peripheral neuropathy 471: Neuron defect induced early behavioral change
2683	944: dimerization, AHR/ARNT	2021: Increase, slincR expression	Jun 30, 2022	Sep 8, 2022	2 AOPs 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity
2684	2021: Increase, slincR expression	2020: Decrease, sox9 expression	Jun 30, 2022	Sep 8, 2022	2 AOPs 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity
2688	18: Activation, AhR	2020: Decrease, sox9 expression	Jun 30, 2022	Apr 13, 2023	2 AOPs 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity
2616	1686: Energy Deposition	1632: Increase in RONS	Mar 28, 2022	Mar 28, 2022	2 AOPs 444: Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability 473: Energy deposition from internalized Ra-226 decay lower oxygen binding capacity of hemocyanin
2724	1821: Decrease, Cell proliferation	2041: Decrease, facial prominence outgrowth	Jul 28, 2022	Apr 2, 2025	2 AOPs 460: Antagonism of Smoothened receptor leading to orofacial clefting 491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
2726	2041: Decrease, facial prominence outgrowth	2042: orofacial cleft	Jul 28, 2022	May 22, 2023	2 AOPs 460: Antagonism of Smoothened receptor leading to orofacial clefting 491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
2743	2050: Increase, developmental abnormalities	350: Increase, Mortality	Aug 28, 2022	Aug 28, 2022	2 AOPs 465: Alcohol dehydrogenase leading to reproductive dysfunction 467: Knickkopf leading to mortality
2732	2043: Decrease, SHH second messenger production	1821: Decrease, Cell proliferation	Aug 23, 2022	Apr 3, 2025	2 AOPs 460: Antagonism of Smoothened receptor leading to orofacial clefting 491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
2731	2040: Decrease, GLI1/2 target gene expression	2043: Decrease, SHH second messenger production	Aug 23, 2022	Apr 3, 2025	2 AOPs 460: Antagonism of Smoothened receptor leading to orofacial clefting 491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
2635	1141: Decreased, Reproductive Success	360: Decrease, Population growth rate	Apr 6, 2022	Apr 6, 2022	3 AOPs 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline 218: Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity 219: Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior
3740	122: Increase, GR activation	1306: Increase, De novo lipogenesis	Feb 12, 2026	Feb 12, 2026	3 AOPs 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
3738	122: Increase, GR activation	2119: Increase, Insulin resistance	Feb 12, 2026	Feb 12, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3743	2408: Increase, Adipose lipolysis	465: Increased, FA Influx	Feb 24, 2026	Feb 24, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3735	1306: Increase, De novo lipogenesis	459: Increase, Liver steatosis	Feb 11, 2026	Feb 11, 2026	3 AOPs 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
3744	465: Increased, FA Influx	459: Increase, Liver steatosis	Feb 24, 2026	Feb 24, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3721	2119: Increase, Insulin resistance	2408: Increase, Adipose lipolysis	Feb 10, 2026	Feb 10, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3633	1767: Increase, Protein oxidation	1446: Decrease, Coupling of OXPHOS	Sep 8, 2025	Jun 23, 2026	3 AOPs 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 332: Reactive oxygen species leading to growth inhibition via protein oxidation and decreased cell proliferation 333: Reactive oxygen species leading to growth inhibition via protein oxidation and cell death
3634	1767: Increase, Protein oxidation	179: Decrease, Fatty acid β-oxidation	Sep 8, 2025	Sep 8, 2025	3 AOPs 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation
3635	179: Decrease, Fatty acid β-oxidation	1771: Decrease, ATP pool	Sep 8, 2025	Sep 8, 2025	3 AOPs 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation
3639	1267: Decrease, Ecdysis motor program activity	993: Decrease, Abdominal muscle contraction	Sep 29, 2025	Sep 29, 2025	3 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade 343: Ecdysone receptor antagonism leading to mortality via mis-timed ecdysone receptor-responsive nuclear receptor cascade
3679	2383: Increase, Hemopericardium	947: Increase, Early Life Stage Mortality	Oct 30, 2025	Oct 30, 2025	3 AOPs 612: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced adenosine triphosphate 613: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via increased reactive oxygen species production 614: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced vascular endothelial growth factor
2424	1023: Increased, Thyroid-stimulating hormone (TSH)	739: Increase, Hypertrophy and proliferation (follicular cell)	Jul 7, 2021	Jul 7, 2021	3 AOPs 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse

Key Event Relationships (KERs)

All KERs